Analysis of Medicare Part D formulary composition since program inception suggests beneficiaries may not be using their open-enrollment periods to reevaluate available plan offerings.
Kirsten J. Axelsen, MS
Advertisement
Articles by Kirsten J. Axelsen, MS
Advertisement
Latest Updated Articles
- Racial Differences in Switching, Augmentation, and Titration of Lipid-lowering Agents by Medicare/Medicaid Dual-eligible Patients
Published: June 1st 2007 | Updated:
- Medicare Part D Formulary Coverage Since Program Inception: Are Beneficiaries Choosing Wisely?
Published: November 15th 2008 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
2
IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?
3
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
4
Belantamab Mafodotin Can Help Fill Access Gaps in BCMA-Directed Myeloma Therapy: Hearn Jay Cho, MD, PhD
5
